Compare PARK & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PARK | CSBR |
|---|---|---|
| Founded | 1972 | 1985 |
| Country | United States | United States |
| Employees | 1212 | N/A |
| Industry | Misc Health and Biotechnology Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.9M | 81.0M |
| IPO Year | N/A | 2015 |
| Metric | PARK | CSBR |
|---|---|---|
| Price | $18.12 | $6.49 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 21.8K | 5.7K |
| Earning Date | 05-13-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 161.11 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,900,000.00 |
| Revenue This Year | $7.06 | $4.84 |
| Revenue Next Year | $6.17 | $11.51 |
| P/E Ratio | $6.47 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.29 | $5.50 |
| 52 Week High | $22.62 | $9.63 |
| Indicator | PARK | CSBR |
|---|---|---|
| Relative Strength Index (RSI) | 44.20 | 66.22 |
| Support Level | $17.33 | $6.14 |
| Resistance Level | $19.14 | $6.96 |
| Average True Range (ATR) | 1.41 | 0.23 |
| MACD | -0.19 | 0.08 |
| Stochastic Oscillator | 10.45 | 63.57 |
Park Dental Partners Inc is a dental resource organization (DRO) operating through its subsidiary. It Provides comprehensive business support services including clinical team members, administrative personnel, facilities and equipment to its affiliated general and multi-specialty dental practices throughout Minnesota and Wisconsin. Its network of affiliated dental practices provides both general and specialty dental services, including oral surgery, periodontics, pediatric dentistry, prosthodontics, endodontics, and orthodontics, under long-term agreements with initial terms of 30-years, with automatic 5-year renewals.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.